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Abstract: Over the past decade, the use of steroids and other performance enhancing 
drugs has shaken the sports world. As athletes search for new and creative ways to gain 
advantages in their disciplines, nearly every major professional U.S. sports league as well as the 
National Collegiate Athletic Association (NCAA) and the United States Olympic Committee 
(USOC) has struggled to develop and enforce new rules against performance enhancing drugs. 
Much of the public attention and regulatory reaction has focused on anabolic steroid and 
hormone use, in part because these drugs appear to be the most commonly used substances and 
also because they are perceived to provide the most significant unfair advantages to athletes.  
However, while these drugs dominate the headlines, cognitive enhancers, also known as 
nootropics, have more quietly begun to assert themselves as the new generation of performance 
enhancement, promising implications far beyond the sports field.  For centuries, certain foods 
and chemicals have been thought to increase cognitive abilities. Even today folk wisdom and 
marketers of supplements advocate the mental boosting properties of vitamins and “brain food” 
ranging from B5 to cranberries to chocolate. But an increasing number of drugs recently have 
been shown to improve memory, concentration and other cognitive ability. Three such drugs, 
Ritalin, Adderall and Provigil, have received Food and Drug Administration (FDA) approval for 
disorders such as narcolepsy and Attention Deficit/Hyperactivity Disorder  (ADHD), but widely 
are being used off-label and without doctor supervision by athletes, students, businessmen, the 
armed forces and even scientists themselves for cognitive enhancement. As with any drug, 
though, unsupervised use poses risks of harmful side effects, drug interactions and addiction, 
risks that are still relatively poorly understood. But given the competitiveness and pressure of the 
modern world, it is hardly surprising that the promise of cognitive enhancers is seductive for so 
many. Furthermore, scientists agree that many more such drugs will be developed in the 
upcoming years. This paper will examine cognitive enhancers and their dramatic, somewhat 
unspoken increasing prevalence in our society. After analyzing efforts to regulate their use by 
various sports organizations and governing bodies, this paper then will address the reasons 
behind, and moral issues raised by the use of cognitive enhancers by others in society, ranging 
from university students to air force pilots.  Finally, this essay will conclude by suggesting 
cognitive enhancers pose a new regulatory challenge that the FDA can no longer ignore: 
Countless Americans from a wide array of backgrounds already use cognitive enhancers illicitly, 
either obtaining them through acquaintances or sometimes by faking symptoms of ADHD or 
narcolepsy to a doctor. Because society stands on the precipice of an age in which psychoactive 
drugs will be used primarily for enhancement, rather than medical treatment, the FDA should 
recognize this new drug use reality and establish a separate, appropriate regulatory scheme for 
cognitive enhancers, one that responds to the common non-medical use of these drugs and best 
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Over the past decade, the use of steroids and other performance enhancing drugs has 
shaken the sports world. As athletes search for new and creative ways to gain advantages in their 
disciplines, nearly every major professional U.S. sports league as well as the National Collegiate 
Athletic Association (NCAA) and the United States Olympic Committee (USOC) has struggled 
to develop and enforce new rules against performance enhancing drugs. Much of the public 
attention and regulatory reaction has focused on anabolic steroid and hormone use, in part 
because these drugs appear to be the most commonly used substances and also because they are 
perceived to provide the most significant unfair advantages to athletes.  However, while these 
drugs dominate the headlines, cognitive enhancers, also known as nootropics, have more quietly 
begun to assert themselves as the new generation of performance enhancement, promising 
implications far beyond the sports field.  For centuries, certain foods and chemicals have been 
thought to increase cognitive abilities. Even today folk wisdom and marketers of supplements 
advocate the mental boosting properties of vitamins and “brain food” ranging from B5 to 
cranberries to chocolate. But an increasing number of drugs recently have been shown to 
improve memory, concentration and other cognitive ability. Three such drugs, Ritalin, Adderall 
and Provigil, have received Food and Drug Administration (FDA) approval for disorders such as 
narcolepsy and Attention Deficit/Hyperactivity Disorder  (ADHD), but widely are being used 
off-label and without doctor supervision by athletes, students, businessmen, the armed forces and 
even scientists themselves for cognitive enhancement. As with any drug, though, unsupervised 
use poses risks of harmful side effects, drug interactions and addiction, risks that are still 
relatively poorly understood. But given the competitiveness and pressure of the modern world, it 
is hardly surprising that the promise of cognitive enhancers is seductive for so many. 
Furthermore, scientists agree that many more such drugs will be developed in the upcoming   4 
years. This paper will examine cognitive enhancers and their dramatic, somewhat unspoken 
increasing prevalence in our society. After analyzing efforts to regulate their use by various 
sports organizations and governing bodies, this paper then will address the reasons behind, and 
moral issues raised by the use of cognitive enhancers by others in society, ranging from 
university students to air force pilots.  Finally, this essay will conclude by suggesting cognitive 
enhancers pose a new regulatory challenge that the FDA can no longer ignore: Countless 
Americans from a wide array of backgrounds already use cognitive enhancers illicitly, either 
obtaining them through acquaintances or sometimes by faking symptoms of ADHD or 
narcolepsy to a doctor. Because society stands on the precipice of an age in which psychoactive 
drugs will be used primarily for enhancement, rather than medical treatment, the FDA should 
recognize this new drug use reality and establish a separate, appropriate regulatory scheme for 
cognitive enhancers, one that responds to the common non-medical use of these drugs and best 
ensures their safety and efficacy.  
 
The History of Cognitive Enhancement 
For hundreds, perhaps thousands of years, people have used foods and other substances 
for their psychoactive effects. 
1 Today, the study of nootropics, or substances that enhance 
cognition, has become a legitimate scientific field, with researchers spending considerable time 
investigating the potential beneficial cognitive properties of various herbs and chemicals found 
in everyday food. 
2 Marketers have been quick to capitalize on such studies (perhaps in some 
                                                 
1 See e.g., Slotkin, J. S, The Peyote Religion: A Study in Indian-White Relations, New York: Octagon - Farrar, Straus 
and Giroux, 1975 (describing the use of Peyote in Indian culture, among other things, to aid “introspection”).  
2 See e.g., “Herbal remedies boost ‘brain power.’” BBC News, April 14, 2000, reporting that University researchers 
“showed that ginkgo biloba can improve the power of concentration, while ginseng sharpens up the memory.” The 
article also notes that these substances have been used in China for thousands of years. 
http://news.bbc.co.uk/2/hi/health/713087.stm    5 
cases helping to fund them) as well as the public’s fascination with “brain foods.” For example, 
industry associations such as The American Egg Board (AEB) and The National Confectioners 
Association (NCA) have each sought to highlight their products’ possible cognitive benefits to 
consumers. The AEB draws attention to choline in eggs: “An essential nutrient, choline plays an 
important neurological role in the development of brain and memory functions. With 125 mg of 
choline, one egg provides at least 22% of an adult’s daily requirement.” 
3 Similarly the NCA 
advocates that eating chocolate can help release “‘feel good’ neurotransmitters,” and “it has been 
suggested that eating fat-containing foods like chocolate might increase endorphins and lift a 
person’s mood.” 
4 The growth in popularity of dietary supplements has further flooded the 
market with products promising to improve both body and mind, and has caused significant 
regulatory battles between the FDA and Congress. 
5  
 
Drugs Often Used as Cognitive Enhancers Today 
But the quest for cognitive enhancement likely has entered a dramatic new phase 
following the discovery that a small group of drugs, approved by the FDA for the treatment of a 
variety of medical conditions, in fact improve memory, concentration and alertness in healthy 
individuals. Although several drugs currently are used off-label to obtain such benefits, Ritalin, 
Adderall and Provigil are among the most popular.  Ritalin, the most common brand name of 
methylphenidate, is the oldest of the three drugs. First marketed in the 1950s to help treat chronic 
fatigue, depression, and psychosis associated with depression, Ritalin saw its use significantly 
                                                 
3 “Egg Nutrition” The American Egg Board website. http://www.aeb.org/Retailers/nutrition.html  
4 “Nutritional Information – The Good News About Chocolate.” National Confectioners Association website. 
http://www.chocolateusa.org/Science-and-Nutrition/good-news-about-chocolate.asp  
5 For an overview of dietary supplement regulation, and in particular the Dietary Supplement Health and Education 
Act of 1994, a bill passed “over the strong objection of the FDA,” see Peter Barton Hutt, “U.S. Government 
Regulation of Food With Claims For Special Physiological Value,” in Mary K. Schmidl and Theodore P. Labuza, 
eds., Essentials of Functional Foods (2000).    6 
increase decades later, when researchers identified its effectiveness in treating ADHD. 
6  As 
doctors began diagnosing ADHD with greater frequency, Ritalin’s use ballooned even more.  
Illustrative of this trend, between 1990 and 1999, methylphenidate manufacturers reported a 500 
percent increase in sales. 
7  Equally remarkable, the Drug Enforcement Agency’s (DEA) 
aggregate production quota for methylphenidate increased from 1,768 kilograms in 1990 to 
14,957 kilograms in 2000; by 2008 the quota had reached 50,000 kilograms. 
8  
As demand for ADHD treatments grew in the 1990s, competitors to Ritalin quickly 
emerged. In 1996, the British company Shire Pharmaceuticals introduced Adderall, a drug 
composed of mixed amphetamines salts that was approved by the FDA for ADHD and 
narcolepsy. 
9 Adderall was marketed as a direct competitor to Ritalin, and its manufacturer was 
even warned by the FDA in 2000 for unsubstantiated comparative claims in journal 
advertisements. 
10  Within a short time, Adderall gained a strong foothold in the drug market.  
While sales of methylphenidate (Ritalin), sold as a generic by various companies, totaled $60 
million in 2004, Adderall XR (extended release) alone boasted $607 million in sales in 2004. 
11 
Adderall’s reputation appeared to be in danger in February 2005 when Health Canada, the 
Canadian governmental drug regulator, suspended the sale of Adderall following reports of 
                                                 
6 “Ritalin.” Center for Substance Abuse Research website, University of Maryland. 
http://www.cesar.umd.edu/cesar/drugs/ritalin.asp  
7 DEA Congressional Testimony of Terrance Woodworth, Deputy Director, Office of Diversion Control, DEA, 
before the Committee on Education and the Workforce: Subcommittee on Early Childhood, Youth and Families, 
May 16, 2000. http://www.usdoj.gov/dea/pubs/cngrtest/ct051600.htm#fig1  
8 Id.; “Aggregate Production Quota History.” (data from 1998-2008) DEA Office of Diversion Control website. 
http://www.deadiversion.usdoj.gov/quotas/quota_history.htm. According to Deputy Director Woodworth’s 
testimony, “Each year, the DEA establishes an aggregate production quota for each Schedule I and II controlled 
substance. This quota is based on sales and inventory data supplied by the manufacturers as well as information 
supplied by the FDA regarding legitimate medical and research needs.” 
9 The immediate release version is indicated for both ADHD and narcolepsy, while a later extended release Adderall 
was approved only for ADHD. FDA approved label for Adderall 20, NDA no. 011522, June 7, 2007. 
http://www.fda.gov/cder/foi/label/2007/011522s040lbl.pdf; FDA approved label for Adderall XR 20, NDA no. 
021303, May 22, 2007. http://www.fda.gov/cder/foi/label/2007/021303s015lbl.pdf.  
10 FDA warning letter dated November 9, 2000. http://www.fda.gov/cder/warn/nov2000/dd9153.pdf  
11 Aaron Smith, “FDA eyes heart risks of ADHD drugs.” February 2, 2006, CNNMoney.com. 
http://money.cnn.com/2006/02/01/news/companies/adhd/index.htm    7 
sudden unexplained death (SUD) in children taking the drug.  However, the FDA chose to not 
emulate their Canadian counterparts, and the ban eventually was lifted in Canada after six 
months and additional investigations. 
12  
The initial success of Ritalin and Adderall appear strongly related to the higher rates of 
ADHD diagnoses. Although a full discussion of the history and current discourse of ADHD is 
outside the scope of this paper, it should be noted that the disorder is plagued by controversy 
both in the medical community and among the general public. 
13 According to the Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), the criteria 
for diagnosis of ADHD includes a series of symptoms relating to hyperactivity and/or inattention 
that causes significant impairment in daily functions. 
14 Although some in the public doubt 
ADHD’s existence, within the medical community a debate continues about how the disorder 
should be diagnosed and treated. 
15 In particular, disagreement exists about the rate of incidence 
of ADHD in the U.S., and how those figures compare to worldwide numbers. 
16  Some 
researchers have questioned whether ADHD is “an American condition,” although other experts 
have countered that ADHD rates worldwide are around five percent, with fewer reported cases in 
areas such as the Middle East and Africa resulting from a dearth of studies and methodological 
differences in those parts of the world. 
17 Still, questions remain regarding when the condition 
warrants medication.  Although the DSM-IV-TR requires that a series of symptoms persist for at 
                                                 
12 Id.; See also, FDA Alert for Healthcare Professionals, 
http://www.fda.gov/cder/drug/InfoSheets/HCP/AdderallHCPSheet.pdf  
13 See generally, Connie Lenz, “Prescribing a Legislative Response: Educators, Physicians, and Psychotropic 
Medication for Children. 22 J. Contemp. Health L. & Pol'y 72.  
14 “Attention-Deficit/Hyperactivity Disorder (ADHD),” DSM-IV-TR, American Psychiatric Association, 2000. 
15 Schonwald A, Lechner E (April 2006). "Attention deficit/hyperactivity disorder: complexities and controversies". 
Curr. Opin. Pediatr. 18 (2): 189–95. 
16 Guilherme Polanczyk et. al. “The Worldwide Prevalence of ADHD: A Systematic Review and Metaregression 
Analysis.” Am J Psychiatry 2007; 164:942-948.  
17 Id.; See also Joseph V. Faraone et. al. “The worldwide prevalence of ADHD: is it an American condition?” World 
Psychiatry. 2003 June; 2(2): 104–113.   8 
least six months before a doctor can diagnose ADHD, qualifying behavior such as “often fails to 
give close attention to details or makes careless mistakes in schoolwork, work, or other 
activities;” “often fidgets with hands or feet or squirms in seat,” and “often talks excessively” 
invite subjective interpretations by both doctors and parents. 
18 Furthermore, additional clinical 
difficulties arise when adult patients complain of ADHD symptoms. Although the DSM-IV-TR 
stipulates that some symptoms must be present before the age of seven, doctors face difficult 
diagnostic decisions when confronted with adults who claim they are experiencing difficulty 
maintaining focus or alertness, especially when the patients insist they may have been suffering 
for years. 
19 In addition, legal responses to ADHD may have contributed to higher rates in the 
U.S. The 1990 Individuals with Disabilities Education Act (IDEA), which mandates special 
education and related services for eligible children, including those with ADHD, may have 
prompted parents to pressure doctors to provide a diagnosis that entitled their children to special 
education benefits. 
20 A 1999 United Nations Study estimated that the U.S. accounts for nearly 
85 percent of world Ritalin use, suggesting that whatever the worldwide ADHD rates, U.S. 
doctors rely heavily on certain medications to treat the disorder. 
21  In 2002, a staff background 
paper for the President’s Council on Bioethics conceded that, “With millions of children 
diagnosed with ADHD, and large amounts of Ritalin and amphetamine being prescribed to treat 
them, it is not surprising that some of these drugs are being resold or given to others for non-
therapeutic use.” 
22 More troublingly, a recent Congressional investigation has alleged that top 
child psychiatry experts from Harvard Medical School and leading advocates of the effectiveness 
                                                 
18 “Attention-Deficit/Hyperactivity Disorder (ADHD),” DSM-IV-TR. 
19 Id.  
20 Staff Background Paper, “Human Flourishing, Performance Enhancement and Ritalin.” The President’s Council 
on Bioethics, 2002. http://www.bioethics.gov/background/humanflourish.html 
21 Quoted in DEA Congressional Testimony of Terrance Woodworth, May 16, 2000. 
22 “Human Flourishing, Performance Enhancement and Ritalin.” See also 22 J. Contemp. Health L. & Pol'y 72, 81.   9 
of psychoactive drugs for ADHD patients may have failed to disclose significant consulting fees 
from ADHD drug producers.  
23 
Another drug that has shown promise in combating ADHD, 
24 but was rejected by the 
FDA for that purpose is Modafinil, marketed most commonly as Provigil. 
25 Approved by the 
FDA in 1998, Provigil currently is indicated for narcolepsy, obstructive sleep apnea and shift 
work sleep disorder. 
26 Unlike Adderall and Ritalin, which are Schedule II drugs, Provigil 
currently is classified as a Schedule IV drug, reflecting less potential for abuse. 
27 However, a 
2009 study published in the Journal of the American Medical Association found greater potential 
for addiction than previously thought, arguing that, “considering
 the increasing use of modafinil, 
these results highlight the
 need for heightened awareness for potential abuse of and dependence
 
on modafinil in vulnerable populations.” 
28  Although subtly stated, the “increasing use” of 
modafinil by “vulnerable populations” mentioned in the JAMA article alludes to its common link 
with Ritalin, Adderall and Provigil: widespread off-label use as a cognitive enhancer, or “smart 
drug.” Provigil, despite being rejected for ADHD use, recorded nearly one billion dollars in sales 
in 2008, an impressive figure for a drug indicated only for narcolepsy, obstructive sleep apnea 
                                                 
23 Gardiner Harris and Benedict Carey, “Researchers Fail to Reveal Full Drug Pay.” The New York Times, June 8, 
2008. http://www.nytimes.com/2008/06/08/us/08conflict.html  
24 See Biederman J, Pliszka SR (March 2008), “Modafinil improves symptoms of attention-deficit/hyperactivity 
disorder across subtypes in children and adolescents.” J. Pediatr. 152 (3): 394–9. Joseph Biederman, a leading child 
psychiatrist, is one of the doctors being investigated by Congress for undisclosed payments by pharmaceutical 
companies, see id.  
25 Elizabeth Mechcatie, “Modafinil to Treat ADHD is Rejected by FDA.” Pediatric News  
September 2006 (Vol. 40, Issue 9, Page 11). 
26 “Provigil Consumer Information.” FDA website.  http://www.fda.gov/cder/consumerinfo/druginfo/provigil.HTM  
27 “Drug Scheduling,” Drug Enforcement Agency, Department of Justice. DEA website. 
http://www.usdoj.gov/dea/pubs/scheduling.html  
28 Nora D. Volkow, et. al. “The Effects of Modafinil on Dopamine and Dopamine Transporters in the Male Human 
Brain.” JAMA. 2009; 301(11):1148-1154. For the response of Modafinil’s manufacturer, Cephalon, see “Cephalon 
Response to JAMA Article ‘The Effects of Modafinil on Dopamine and Dopamine Transporters in the Male Human 
Brain.’” http://www.cephalon.com/media/on-the-record/cephalon-response-to-jama-article-the-effects-of-modafinil-
on-dopamine-and-dopamine-transporters-in-the-male-human-brain/    10 
and shift work sleep disorder. 
29 The stark reality is that many otherwise healthy individuals in 
the U.S. are using Ritalin, Adderall, Provigil and other similar drugs for cognitive enhancement.  
The following sections of this paper examine how these drugs are increasingly being used in 
professional sports, where small gains in performance can translate into large increases in salary, 
and how the general public is increasingly experimenting with non-medical use of cognitive 
enhancers as well.   
 
Cognitive Enhancers in Sports 
The Ethics and Use of Performance Enhancing Drugs in Sports   
The use of performance enhancing drugs in sports, in particular anabolic steroids and 
human growth hormone (HGH) has generated intense public discussion and increased regulatory 
oversight over the past few decades. Although the new steroid rules in baseball in 2005, 
30 the 
introduction of drug testing in professional golf in 2008, 
31 and the establishment of the World 
Anti-Doping Agency in 1999 
32 demonstrate that most fans and sports officials seem to favor 
strictly controlling such drug use and punishing those who break the rules, the underlying ethical 
and policy justifications are far from clear. For example, although doctors generally agree that 
anabolic steroids promote muscle growth, 
33 there is a more tenuous connection between 
                                                 
29 “‘Smart Drug’ Provigil May Be Addictive.” The Associated Press, March 18, 2009. 
http://www.newsmax.com/health/Provigil_addictive_smart/2009/03/18/193213.html  
30 “MLB, MLBPA announce new drug agreement.”  Press release, Major League Baseball and Major League 
Baseball Players Association, November 15, 2005 (describing increased penalties for those testing positive for 
steroids, including a 50-game suspension for first time offenders). 
http://mlbplayers.mlb.com/pa/releases/releases.jsp?content=111505  
31 “PGA Tour begins a new era with drug testing this week at AT&T National.” July 2, 2008, The Association Press. 
http://www.pga.com/2008/news/pgatour/07/02/drug060208.ap/index.html?eref=sitesearch. For women’s golf, See 
“LPGA releases Prohibited Substance Classes and Prohibited Methods List for drug-testing program. March 21, 
2007, LGPA website. http://www.lpga.com/content_1.aspx?pid=10100&mid=4  
32 “WADA History,” World Anti-Doping Agency website,  
http://www.wada-ama.org/en/dynamic.ch2?pageCategory.id=253  
33 Cf. “Anabolic Steroid Act of 2004,” Statement of Joseph T. Rannazzisi, Deputy Director, Office of Diversion 
Control, DEA, Before the House Committee on the Judiciary, Subcommittee on Crime, Terrorism, and Homeland   11 
resulting increased muscle mass and improved performance in sports.  Many sports such as 
baseball, basketball and even seemingly pure strength sports such as weightlifting require a blend 
of strength, endurance and technique to be successful at the professional level. According to 
David Greenblatt, chief of clinical pharmacology at the New England Medical Center Hospital 
and professor of psychiatry and medicine at Tufts University School of Medicine, there exists 
“no scientific evidence to show that anabolic steroids would enhance performance in any athlete. 
For instance, no one ha[s] scientifically demonstrated that any possible improvements in strength 
would translate into enhanced performance for football players.” 
34  In fact, in Hill v. National 
Collegiate Athletic Assn., a California appeals court, relying on the testimony of several 
similarly-minded doctors and NCAA drug committee members, found that the “NCAA failed to 
carry its burden of proving that anabolic steroids enhance performance in any NCAA sport.” 
35 
But notwithstanding unanswered questions of the metaphysical causation between steroids and 
performance enhancement, their widespread use suggests that many professional athletes believe 
they provide the tools to enhance performance and prolong careers. Even assuming this is true, 
though, steroids hardly are magic pills enabling anyone to become a professional athlete. In the 
words of one scholar, “As such, they may bring out the inherent ability of the athlete by assisting 
him or her to overcome certain performance inhibitors such as passiveness, insufficient strength, 
underdeveloped musculature, premature exhaustion, and so forth.” 
36 Although steroids alone 
likely cannot turn the average American into a professional athlete, they nevertheless are almost 
universally condemned.  One justification for this disapproval is that given the significant health 
                                                 
Security, March 16, 2004. (Arguing that statutory requirements to demonstrate a substance promotes muscle growth 
substantially hampers DEA efforts to classify new steroids as Schedule III anabolic steroids).  
34 Quoted in Hill v. National Collegiate Athletic Assn., 18 Cal. App. 4th 1290, 1317 (Cal. Ct. App. 1990) 
35 18 Cal. App. 4th 1290, 1318. This opinion was superceded by a grant of review under California law.  
36 Quoted in Michael H. Shapiro, “The Technology of Perfection: Performance Enhancement and the Control of 
Attributes.” 65 S. Cal. L. Rev. 11, footnote 319.    12 
risks steroids pose, allowing their use essentially forces athletes to sacrifice physical well-being 
to compete at the highest professional levels. 
37 But as Judge Richard Posner succinctly has 
countered, “A football lineman will not be criticized for blowing himself up into a 400-pound 
freak if he does it without the aid of drugs, even though the long-term effects on his health of the 
added weight are very bad and even though his weight gain may place pressure on other linemen 
to match it.” 
38  
 
The Shift to Cognitive Enhancers in Sports 
Whatever the counterarguments, most U.S. sports leagues have enacted strict policies 
against steroid use. In the wake of such tight regulation, athletes appear to be turning to cognitive 
enhancers for an edge. Recent trends in Major League Baseball (MLB) provide an illustrative 
example. For decades, amphetamines, known as “greenies” were a mainstay in baseball locker 
rooms. Some players have claimed that amphetamine use was so widespread that large 
communal jars of pills were openly available in clubhouses to any player who wanted them. 
39 
Because amphetamines improve concentration, reaction times and provide energy boosts, they 
offered significant benefits to professional baseball players, who greatly rely on hand-eye 
coordination and stamina during their 162-game season. 
40 In fact, one doctor who served as the 
New York Mets team psychiatrist from 1985 to 2003 publicly stated that the “No. 1 drug use of 
sports is really amphetamines… [they]are the real performance-enhancing drugs that people 
                                                 
37 “NIDA InfoFacts: Steroids (Anabolic-Androgenic).” National Institute of Drug Abuse, National Institutes of 
Health, http://www.nida.nih.gov/Infofacts/steroids.html  
38 “Doping Athletes – Posner’s Comments.” The Becker-Posner Blog, August 27, 2006. http://www.becker-posner-
blog.com/archives/2006/08/doping_athletes.html   
39 Hustle: The Myth, Life and Lies of Pete Rose. Michael Sokolove, Simon and Schuster, 2005. p. 78.  
40 Michael S. Schmidt, “Baseball is Challenged on Rise in Stimulant Use.” January 16, 2008. The New York Times. 
http://query.nytimes.com/gst/fullpage.html?res=9D03E7DB103AF935A25752C0A96E9C8B63&sec=&spon=&pag
ewanted=all    13 
should always have been worried about.” 
41 But even as more sophisticated stimulants such as 
Adderall (mixed amphetamine salts), Provigil and Ritalin were developed by major 
pharmaceutical companies, stimulants were banned only in the 2006 season, several years after 
the steroid and HGH scandals had been exposed in baseball.  Even under the current regime, 
stimulant users face lesser penalties than steroid abusers: while first time steroid offenders 
receive a mandatory 50-game suspension, first time stimulant users simply face mandatory 
follow-up testing, with a second positive result leading to a 25-game suspension. 
42  
Major League Baseball’s Joint Drug Prevention and Treatment Program, the official 
name of baseball’s new drug policy, was heavily negotiated by MLB and the Major League 
Baseball Players’ Union (MLBPA). The agreement allows for a Therapeutic Use Exemption 
(TUE) of banned substances for “medically appropriate prescription[s] provided by a duly 
licensed physician.” 
43 Interestingly, during the Congressional oversight hearings of the Mitchell 
Report (MLB’s investigation of steroid use in the sport), Congressman John Tierney obtained 
previously unreleased data showing that the number of TUE’s for ADHD increased from 28 
players during 2006, the first year of the ban, to 103 in 2007. 
44 Although 103 players represent 
about 8 percent of all MLB athletes, a rate only slightly higher than generally-agreed national 
ADHD rates, according to Congressman Tierney, “When you see the number 28 one year go all 
the way to 103, it makes you think that we have a loophole here with performance-enhancing 
drugs.” 
45 Some players, however, have defended their TUE, and even becomes advocates for 
                                                 
41 Id.  
42 “Major League Baseball’s Joint Drug Prevention and Treatment Program.” MLB and MLBPA, 2005, p. 17. 
http://mlbplayers.mlb.com/pa/pdf/jda.pdf  
43 Id. p. 10.  
44 Preliminary Transcript, “The Mitchell Report: The Illegal Use of Steroids in Major League Baseball.” January 15, 
2008, House of Representatives, Committee on Oversight and Government Reform. 
http://oversight.house.gov/documents/20080205163114.pdf  
45 In 2009, 106 players received TUE for ADHD. Christian Red and Nathaniel Vinton. “Report: Amphetamines Still 
in Play in MLB. January 9, 2009. New York Daily News.   14 
increased awareness and acceptance of ADHD. Adam LaRoche, a first-baseman for the 
Pittsburgh Pirates, openly has talked to the media about his ADHD diagnosis and use of Ritalin 
during the baseball season. LaRoche, who had been benched by past teams for being a “lazy” 
player, credits Ritalin for helping his performance on the field, “It helps me to focus for three 
hours when I'm playing and not be spacing out or thinking about a million different things. We're 
still experimenting with dosages.” 
46 LaRoche has also stated that several teammates privately 
have asked to discuss ADHD with him, and LaRoche suspects, “a ton of adults have it — maybe 
some so mildly that they don't really know.” 
47 Publicly admitting to any psychiatrist disorder is 
embarrassing and potentially financially damaging to an athlete’s career, and consequently it is 
unfair to question the motives of all players requesting ADHD TEU’s. However, given the 
potential for performance enhancement that stimulants such as Adderall and Ritalin can provide, 
it is noteworthy that few, if any players, use Atomoxetine (marketed as Strattera), the only non-
stimulant medication FDA-approved for ADHD. 
48 
Baseball, is not the only sport, though, that has been forced to confront cognitive 
enhancers. Because of Congressional oversight of baseball, more data has emerged concerning 
stimulant use in that sport than in others. However, in the 2005 NCAA Study of Substance Use 
Habits of College Student-Athletes, a study conducted every four years since 1997, the 
organization reported that while anabolic steroid use was down from the previous study, 
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amphetamine use “has continually increased since 1997.” 
49 The report also concluded that two-
thirds of amphetamine use by college athletes began in high school. 
50 Interestingly, though, 
based on athletes’ self-reported answers to questionnaires given to them by the NCAA, the 
organization concluded that, “use of amphetamines to improve athletic performance appears to 
be down significantly from the 2001 study. The main reason stated for using amphetamines is for 
the treatment of attention deficit disorder followed by using to get more energy.” Although this 
statement reveals a somewhat dubious distinction among both athletes and NCAA officials 
between the use of stimulants such as Ritalin and Adderall to boost energy and mental functions 
versus their use as “performance enhancers,” both Adderall and Ritalin are banned from NCAA 
competition, unless the athlete receives a Medical Exemption. 
51 However, in guidance 
explaining medical exemptions to its athletes, the NCAA arguably sends mixed messages about 
the appropriate circumstances for which ADHD medication should be used.  The memo 
specifically names Ritalin and Adderall, and although it warns that those seeking to use the drugs 
must follow NCAA protocol, it notes, “Frequently a student-athlete may find that the demands of 
college present difficult learning challenges. They may realize that some of their teammates are 
benefitting [sic] from the use of these medications, and figure they should ask their team 
physician or family doctor to prescribe the same for them.” 
52 Arguably such advice further 
confuses an already murky boundary increasing ADHD awareness and encouraging cognitive 
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enhancement in student-athletes; however, the statement likely is reflective of NCAA attempts to 
offer realistic alternatives to its athletes given the prevalence of Ritalin and Adderall on college 
campuses, a phenomenon explored later in this essay.  
The use of cognitive enhancers has crept into numerous other sports. Provigil, a stimulant 
that currently is not banned by the NCAA, but is on the World Anti-Doping Agency’s (WADA) 
Prohibited List, 
53 was found in six U.S. athletes, including three hurdlers, two sprinters and a 
hammer thrower during two track and field meets in 2003. 
54 The Nevada Athletic Commission, 
which relies heavily on the WADA Prohibited List to define its illegal substances,
55 removed 
popular mixed martial artist Tim Credeur from a televised match, but declined to punish him 
further in 2008 following a positive test for Adderall. 
56 
It is difficult to know the real reasons athletes take cognitive enhancers like Ritalin, 
Adderall and Provigil. Some may be seeking a simple boost in energy, similar to athletes’ 
amphetamine use in past decades. Others may appreciate more specific effects, like increased 
focus during competition. And some no doubt genuinely use them to treat ADHD, real or 
perceived.  Another class of drugs that further blurs the line between performance and cognitive 
enhancement are beta-blockers. Beta-blockers reduce blood pressure by blocking the effects of 
adrenaline. Consequently, they act primarily on the heart, lowering the rate and force of 
heartbeats. 
57 However, beta-blockers also can nullify symptoms of anxiety. For instance, 
classical musicians reportedly have been using them for years because of their ability to decrease 
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hand tremor and nervousness during performance. 
58 The ethics of their use during competitions 
and auditions is still debated within the music community. 
59 The WADA has banned beta-
blockers in several sports, including golf, gymnastics, shooting and wrestling. 
60 The 
International Olympic Committee, using the WADA guidelines, stripped a North Korean athlete 
of silver and bronze medals in Air Pistol competitions after testing positive for the beta-blocker 
propranolol. 
61 And following rumors that some of its top competitors were using similar drugs, 
the Professional Golf Association (PGA) also began testing for beta-blockers in 2008, as part of 
its new comprehensive policy against performance enhancing drugs. 
62 Because beta-blockers are 
not psychoactive drugs, it may be difficult to classify them as cognitive enhancers. However, if 
beta-blockers are being used to control the physical manifestations of a psychological 
phenomenon, namely anxiety, a closer nexus to cognitive enhancers emerges. 
63 Presumably 
beta-blockers’ relatively limited ban in sports stems from a belief that a lowered heart rate and 
control of nerves offer significant performance advantages only in certain sports, particularly 
ones that rely on fine-motor skills. And although no data exists on how many athletes use beta-
blockers, it is not difficult to imagine a wide range of situations where the ability to suppress 
symptoms of anxiety would be greatly beneficial: from the basketball player who needs to sink 
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the winning free throw to the football place kicker asked to win the game with a field goal, it 
would not be surprising if beta blocker was higher than currently suspected.  
 
Cognitive Enhancers in Schools, Business, the Scientific Community and Armed Forces 
Given the large salaries and performance bonuses that professional athletes can receive, it 
is not remarkable that some seek any edge that modern medicine can provide. But cognitive 
enhancers’ impact on society stretches far further than the sports field. High achievers from 
many walks of life had learned that stimulants such as Adderall, Ritalin and Provigil can provide 
a mental edge at work and at school. Such widespread non-medical use of cognitive enhancers 
raises new ethical and legal issues that the medical community and FDA should no longer 
ignore, and it may challenge the public’s perception of performance enhancement generally.  
  Teenaged and college-aged students often are the first to seek out and master the latest 
consumer technologies. The same appears to be true for cognitive enhancers: by all accounts, 
students represent a large contingent of the countless Americans using psychoactive drugs to 
“upgrade” their brains. Much like the “greenies” that were available to athletes for decades 
before the invention of drugs like Adderall, products like “No-Doze” or even coffee have fueled 
exam cramming and late-night paper writing for years. But students have been quick to 
experiment with the new current generation of cognitive enhancers. Although reliable statistics 
are difficult to obtain, one study of Harvard and University of Michigan researchers found that 
nearly seven percent of college students admitted to non-medical use of Ritalin, Dexedrine or 
Adderall; at some colleges, the rate was as high as 25 percent. 
64 A U.S. government study also 
reported that “full-time college students aged 18 to 22 were twice as likely as their counterparts 
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who were not full-time college students to have used Adderall nonmedically in the past year.” 
65 
Anecdotally, as an article in the Harvard Crimson opined, “Everyone on campus knows about 
illegal Adderall or Concerta usage and knows where these drugs can be obtained quickly.” 
66 A 
simple Google search of Adderall reveals many school newspaper articles acknowledging 
widespread campus use of the drug. 
67 
  But curious college students are not the only non-athletes using cognitive enhancers. 
Adderall usage is also common on Wall Street, where the pressure to perform can be as great as 
on any playing field or classroom. 
68 In 2003, the U.S. Air Force released guidelines regulating 
its approved use of Provigil as a “Go Pill” for fighter pilots to combat fatigue. 
69 Since 
introducing that policy, the Air Force also has prosecuted airmen for illegal distribution and use 
of Adderall. 
70 Perhaps most intriguingly, an informal survey by the science journal Nature 
revealed that approximately 20 percent of respondents, mainly scientists, used cognitive 
enhancers. 
71 More specifically, 62 percent of this group admitted using Ritalin, 44 percent 
reported using Provigil and 14 percent utilized beta-blockers. 
72  In another anonymous 
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questionnaire by researchers, a British professor offered a typical explanation for taking Provigil, 
claiming it “increases mental energy [and] improves sustained, hard thinking.” 
73 Such use 
among intellectuals should not be surprising: Benzedrine, an amphetamine mixture and precursor 
to modern cognitive enhancers, was used by several great minds. Jack Kerouac was said to have 
written his novel On the Road largely under the influence of the drug, while Jean-Paul Sartre 
said amphetamines provided him with, “a quickness of thought and writing that was at least three 
times my normal rhythm.”  
74  One of the greatest mathematicians of the 20
th century, Hungarian 
Paul Erdos, is reputed to have been so addicted to Benzedrine that a close friend challenged him 
to a bet to quit the drug for a month. Erdos won the wager, but chided his friend, “You’ve 
showed me I'm not an addict. But I didn't get any work done. I'd get up in the morning and stare 
at a blank piece of paper. I'd have no ideas, just like an ordinary person. You've set mathematics 
back a month.” 
75  
 
The New Ethics of Performance Enhancement 
How should society respond to such prevalent use of drugs like Ritalin, Adderall and 
Provigil?  Recently, several prominent scholars from medicine, law and bioethics publicly 
advocated research into broader non-medical use of cognitive enhancers, and encouraged the 
public to resist attaching a stigma to their use. 
76 Indeed, a national discussion concerning 
cognitive enhancers inevitably will raise several contentious issues and may have implications 
for the ethical debate over steroids in sports. For instance, Stanford Law School Professor Henry 
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Greely (one of the leading advocates for greater scientific and public debate on the use of 
cognitive enhancers), Judge Posner and many others have noted that unlike steroid use in sports, 
cognitive enhancers offer “the potential for real personal and social benefits.” 
77 This assertion is 
debatable because thousands of athletes stand to significantly improve their livelihood and 
financial security by steroids. Furthermore, although the actual social benefit is questionable, 
there seems to exist substantial marketing value in athletes who can hit more home runs, throw 
longer passes, and knock other men out faster in a ring. But the sports analogy nevertheless 
raises an important point: for most Americans today, performance-enhancing drugs essentially 
serve an entertainment function.  Fans may feel duped when an athlete’s superior physical ability 
is revealed to partly result from steroids, but the public’s outrage against steroid use in sports 
may dissipate once performance-enhancing drugs become relevant to the average American.  To 
be sure, not everyone is welcoming of the age of cognitive enhancers; comparisons already exist 
between the “taint” of the sports steroid era and the effects of Adderall on college campuses, 
with some even suggesting drug testing students before exams. 
78 Interestingly, students’ use of 
cognitive enhancers challenges another oft-repeated anti-steroid justification that their use sets a 
bad example for children. 
79  This rationale may be less credible if children – or even their 
parents – come to view cognitive enhancers as a vehicle for educational and career benefits. 
Indeed, such drugs cannot be explained away as minor study aids. Some bioethicists have 
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likened their use to drinking coffee during late nights or smoking cigarettes to calm nerves. 
80 
But such an analogy underestimates the sophistication and neurochemical effect of drugs such as 
Ritalin, Adderall and Provigil. And although a philosophical debate is likely to continue  over 
whether cognitive enhancers actually increase intelligence and complex thinking or simply 
provide the tools to study longer and more effectively (a causation question similar to that of 
anabolic steroids and increased athletic performance, see supra), 
81 it is important to remember 
that scientists agree that new generations of cognitive enhancers already are being developed by 
pharmaceutical companies. 
82 As the use of cognitive enhancers becomes more common, society 
will need to redefine their conceptions of “cheating” and legitimate enhancement. For example, 
the use of beta-blockers during a presidential debate may remain unpalatable to the majority of 
Americans, while perhaps a surgeon’s use of Ritalin during an operation, or an Air Force pilot’s 
use of Provigil during combat will seem justified. Finally even more difficult ethical questions 
likely will be posed in the longer term, for example, whether employers can mandate taking 
Adderall as a condition of employment or whether governments should create tighter patent 
protections and distribution controls to ensure certain countries will have a monopoly on the 
most effective cognitive enhancers.  
 
The Future Regulation of Cognitive Enhancers  
Such moral and ethical questions however, are premature until a regulatory regime is 
developed to ensure the safety and efficacy of drugs used specifically for cognitive enhancement. 
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Drugs such as Ritalin, Adderall and Provigil are regulated by the FDA for certain medical 
indications, but the FDA can no longer ignore that many Americans are seeking these drugs for 
non-medical, cognitive enhancement purposes. Such drug use, even if often illegal, is no longer 
on the periphery of society.  Although the DEA and FDA could reduce aggregate production 
quotas to curb illicit use of cognitive enhancers, considering that a market demand clearly exists 
for such drugs, and that several more such drugs are likely to appear soon (albeit for other 
medical indications), the FDA should recognize cognitive enhancers as a separate product class 
for the purposes of regulation. Medical and technological developments in the past have caused 
the FDA to create new categories of regulated products, such as dietary supplements and 
biologics, and a similar time has come for the administration to create an appropriate regulatory 
regime for cognitive enhancers.
83 
  Current FDA regulation of cognitive enhancers is inadequate for several reasons. By 
ignoring the cognitive enhancement function of certain drugs, the FDA encourages a black 
market for this use. For example, in addition to buying, selling or forging prescriptions, students 
even fake the symptoms of ADHD or narcolepsy to doctors to gain access to cognitive 
enhancers. 
84 Also, the manufacturers of these drugs are fully aware of the lucrative off-label 
market for their products. And although FDA rules prohibit advertising off-label uses of 
medication, some companies have tested the boundaries in an effort to exploit the underground 
popularity of cognitive enhancers.  For example, the makers of Adderall were warned by the 
FDA in 2008 for releasing a testimonial of television star Ty Pennington on youtube.com in 
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which he claimed Adderall, “literally changed my life, and gave me the confidence to achieve 
my goals.” 
85 
Off-label drug use has been a controversial topic in drug law for many years. But the off-
label usage of drugs such as Ritalin, Adderall and Provigil as cognitive enhancers is too vast to 
ignore and has proven to be an exceptional case.  The cognitive enhancers of the future are drugs 
likely to be discovered during the development of medical-use drugs like new Alzheimer’s 
medications. 
86 But by acknowledging cognitive enhancers as a distinct class, the FDA can direct 
manufacturers to perform detailed studies to better establish efficacy and appropriate dosages for 
an enhancement indication.  Currently, individuals are left to guess or consult their friends or the 
Internet concerning correct dosing, potential side effects and drug interactions. Adderall, Ritalin 
and Provigil all have potential side effects, and all pose serious health risks when not used as 
directed. 
87 In addition, government research suggests that non-medical Adderall users are 
significantly more likely than their peers to abuse alcohol and “recreational drugs” such as 
marijuana, cocaine and pain killers.
88  In an increasingly competitive world, it is understandable 
that people look for new ways to gain a mental edge.  But until the FDA regulates cognitive 
enhancers directly, rather than turn a blind eye to their off-label and unsupervised use, it invites 
misunderstanding and abuse of these drugs among the public.  And although individual 
institutions in society such as sports governing bodies, school systems and the armed forces may 
be the final arbiters about the permissibility of cognitive enhancers in their individuals fields of 
endeavor, rather than establish their own rules on an ad hoc basis, many organizations likely 
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would welcome increased regulation by the FDA to ensure efficacy and safety as well as 
establish guidelines for use, labeling and dosage.  
  Ultimately, however, the FDA is not in the business of regulating the practice of 
medicine.  The medical community, and perhaps psychiatrists in particular need to take a more 
critical look at ADHD.  The subjectivity of ADHD symptoms, the fact that doctors frequently 
can be manipulated by patients into diagnosing the disorder, and the reality that so many 
supposedly healthy individuals believe ADHD medication improves their lives suggests 
diagnostic criteria and treatment options of ADHD need refining, especially when doctors 
diagnose adult patients.  Nearly everyone loses focus and becomes forgetful at times, and it is not 
surprising for athletes and others to wonder if they suffer from some form of attention deficit, 
however mild, especially if they see colleagues benefiting from drug use.  However, an ADHD 
diagnosis, like that of any mental disorder, carries a social stigma, and could have legal 
implications for a person’s employment or health insurance. Thus, even if non-medical use of 
drugs like Ritalin, Adderall and Provigil becomes an accepted practice, the line between 
cognitive enhancement and treatment for ADHD will continue to be blurred until the medical 
community can provide a clearer distinction between the two. The DSM-V, an updated version 
of the American Psychiatric Associations manual for mental disorders currently is being 
prepared and is expected to be released in 2012, providing a timely opportunity for renewed 
discussion regarding the unresolved clinical issues surrounding ADHD. 
89 Finally, assuming that 
the FDA would require prescriptions for certain cognitive enhancers, the broader medical 
community will need to take a position on how it views its role as gatekeepers between patients 
and such drugs.  This may be a particularly complicated issue; although some commentators 
have noted that enhancement questions already confront doctors working in areas such as plastic 
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surgery and fertility clinics, the analogy is not incomplete. 
90 Cognitive enhancers will raise even 
more complicated ethical issues for doctors than current enhancement procedures because their 
use will be on a much larger scale, and if ADHD diagnoses are a guide, there will be significant 
pressure for patients to begin them at an earlier age. 
The era of cognitive enhancers is not on the horizon; it is already here. Athletes, 
businessmen, scientists and students have discovered their potential and have begun to 
incorporate them into their lives, legally and otherwise. It is time for the FDA and the medical 
community to acknowledge their widespread use.  By recognizing cognitive enhancers as a 
separate class of product regulation, the FDA can direct manufacturers to begin to investigate the 
short and long-term effects of these drugs and determine appropriate dosage rates and labeling.  
And by acknowledging a non-medical, enhancement indication for psychoactive drugs, the FDA 
will be ready for the future generation of cognitive enhancers and be equipped to protect the 
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